结肠癌中ABCG2基因多态性与伊立替康疗效的相关性研究  

The polymorphism of ABCG2 SNPs in colon cancer and its clinical association with irinotecan treatment

作　　者：吴慧娟[1] 吴红波[1] 邹宏志[1] 陈利娟[1] 赵艳秋[1] 

机构地区：[1]郑州大学附属肿瘤医院(河南省肿瘤医院)内科,河南郑州450008

出　　处：《中国现代医学杂志》2014年第7期48-50,共3页China Journal of Modern Medicine

摘　　要：目的检测结肠癌中ABCG2基因SNP多态性,探讨其与伊立替康疗效的相关性。方法收集该院2011年1月~2013年2月应用伊立替康治疗的结肠癌患者92例,34 G〉A、376 C〉T、421 C〉A位点SNPs多态性测定使用Real-Time PCR Taqman分析。结果 34 G〉A等位基因的频率为70.6%和29.4%,376 C〉T等位基因的频率为92.9%和7.1%,421 C〉A等位基因的频率为70.1%和29.9%。34 G〉A位点G/G、G/A、A/A基因型的临床获益患者分别占了68.2%、76.2%和66.7%,各基因型之间差异无显著性（P〉0.05）。376 C〉T位点C/C、C/T和T/T基因型的临床获益患者分别占了72.8%、66.7%和50.0%,各基因型之间差异无显著性（P〉0.05）。421 C〉A位点C/C、C/A、A/A基因型的临床获益患者分别占了88.6%、61.0%和42.9%,各基因型之间差异具有显著性（P〈0.05）。结论检测ABCG2基因421 C〉A位点SNP的多态性有利于伊立替康临床疗效的早期评估。[ Objective ] To investigate the polymorphism of ABCG2 SNPs in colon cancer and explore its clinical association with irinotecan treatment. [ Methods ] 96 patients with NSCLC were enrolled in our study. Another 40 healthy person were used as a normal control The genotypes of IL13Rα2 SNPs（rs17095919） was performed using the standard TaqMan assays. [Results] The allele frequency of 34 G〉A was 70.6% and 29.4%, 376 C〉 T allele was 92.9% and 7.1%, and 421 C〉A was 70.1% and 29.9%. The Clinical benefit of G/G, G/A, A/A genotype in 34 G〉A locus was 68.2%, 76.2% and 66.7%. There was no significant difference among the genotypes（P 〉0.05）. The Clinical benefit of C/C, C/T, T/T genotype in 376 C〉T locus was 72.8%, 66.7% and 50.0%. There was no significant difference among the genotypes （P 〉0.05）. The Clinical benefit of C/C, C/A, and MA genotype in 421 C〉A locus was 88.6%, 61.0% and 42.9%. There was significant difference among the genotypes （P 〈0.05）. [Conclusion] Detection polymorphism of 421 C〉A loci in ABCG2 gene would contribute to early assess the clinical efficacy of irinotecan treatment in colon cancer patients.

关 键 词：结肠癌 ABCG2基因 单核苷酸多态性 

分 类 号：R735.35[医药卫生—肿瘤]